Registration No. 33-
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM S-3
REGISTRATION STATEMENT
Under
The Securities Act of 1933
----------
GRAHAM-FIELD HEALTH PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware 11-2578230
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
400 Rabro Drive East
Hauppauge, New York 11788
(516) 582-5900
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
Irwin Selinger
Chairman of the Board and
Chief Executive Officer
Graham-Field Health Products, Inc.
400 Rabro Drive East
Hauppauge, New York 11788
(516) 582-5900
(Name, address, including zip code, and telephone number, including area
code, of agent for service)
Copy to:
Richard S. Kolodny
Vice President, General Counsel
Graham-Field Health Products, Inc.
400 Rabro Drive East
Hauppauge, New York 11788
(516) 582-5900
Approximate date of commencement of proposed sale to the public: As soon as
practicable after the effective date of the Registration Statement.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. |_|
If any of the securities being registered on this form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. |X|
CALCULATION OF REGISTRATION FEE
<TABLE>
================================================================================================================================
<CAPTION>
Proposed Proposed
Amount Maximum Maximum Amount of
Title of Shares to be Aggregate Price Aggregate Registration
to be Registered Registered Per Unit(1) Offering Price(1) Fee
- --------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock,
$.025 Par Value 50,000 $8.125 $406,250 $138
================================================================================================================================
</TABLE>
(1) Estimated solely for purposes of calculating the registration fee in
accordance with Rule 457(c) based on average high and low prices for
the Company's Common Stock on the New York Stock Exchange consolidated
reporting system on July 31, 1996.
The Registration hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
================================================================================
<PAGE>
GRAHAM-FIELD HEALTH PRODUCTS, INC.
<TABLE>
<CAPTION>
Registration Statement Regulation S-K
Item Number and Caption Item No. Location in Prospectus
----------------------- -------- ----------------------
<S> <C> <C>
1. Forepart of the Registration
Statement and Outside Front Cover
Page of Prospectus..................................... 501(a) Cover Page of Registration
Statement
(b) This Cross-Reference Sheet
(c) Inside Front Cover
2. Inside Front and Outside Back
Cover Pages of Prospectus.............................. 502(a) Inside Front Cover
(b) Not Applicable
(c) Inside Front Cover
(d) Not Applicable
(e)-(g) Not Applicable
3. Summary Information, Risk Factors
and Ratio of Earnings to Fixed
Charges................................................ 503(a) Prospectus Summary
(b) Prospectus Summary; The
Company
(c) Not Applicable
(d) Not Applicable
4. Use of Proceeds.......................................... 504 Use of Proceeds
5. Determination of Offering Price.......................... 505 Not Applicable
6. Dilution................................................. 506 Not Applicable
7. Selling Security Holders................................. 507 Selling Stockholders
8. Plan of Distribution..................................... 508(a)-(b) Not Applicable
(c)-(d) Plan of Distribution
(e)-(j) Not Applicable
9. Description of Securities to be
Registered............................................ 202 Not Applicable
10. Interests of Named Experts and
Counsel................................................ 509 Not Applicable
11. Material Changes......................................... Material Changes
12. Incorporation of Certain Information Legal Proceedings
by Reference........................................... Incorporation of Certain
13. Disclosure of Commission Position on Documents by Reference
Indemnification for Securities
Act Liabilities........................................ 510 Not Applicable
</TABLE>
- 2 -
<PAGE>
- --------------------------------------------------------------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
- --------------------------------------------------------------------------------
PROSPECTUS
- ----------
SUBJECT TO COMPLETION, DATED August 1, 1996
GRAHAM-FIELD HEALTH PRODUCTS, INC.
50,000 SHARES
COMMON STOCK
______________________________
All of the shares of the common stock, par value $.025 per share (the
"Common Stock") of Graham-Field Health Products, Inc. (the "Company"), offered
hereby are being sold by the holders of the Common Stock named herein under
"Selling Stockholders" (the "Selling Stockholders"). The outstanding Common
Stock of the Company is, and the Common Stock offered hereby will be, listed on
the New York Stock Exchange (the "NYSE"). On July , 1996, the last reported sale
price of the Common Stock on the NYSE was $8.125 per share.
The Company will not receive any of the proceeds from the sale of the
Common Stock. Any or all of such Common Stock covered by this Prospectus may be
sold, from time to time, by means of ordinary brokerage transactions or
otherwise. See "Plan of Distribution."
______________________________
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
______________________________
Information contained herein is subject to completion or amendment. A
registration statement relating to these securities has been filed with the
Securities and Exchange Commission. These securities may not be sold nor may
offers to buy be accepted prior to the time the registration statement becomes
effective. This prospectus shall not constitute any offer to sell or the
solicitation of any offer to buy nor shall there be any sale of these securities
in any State in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such State.
______________________________
The date of this Prospectus is August_____, 1996
- 3 -
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information can be inspected and copied at the public
reference facilities maintained by the Commission at Judiciary Plaza, 450 Fifth
Street, N.W., Room 1024, Washington, D.C. 20549 and at its regional offices at
500 West Madison Street, Suite 1400, Chicago, Illinois 60661 and at 75 Park
Place, New York, New York 10007. Copies of such materials can be obtained from
the Public Reference Section of the Commission, 450 Fifth Street, N.W.,
Washington, D.C. 20549, on payment of prescribed charges. Such reports, proxy
statements and other information concerning the Company can also be inspected at
the offices of the New York Stock Exchange, 20 Broad Street, New York, New York
10005.
The Company has filed with the Commission a registration statement on Form
S-3 (the "Registration Statement") under the Securities Act of 1933, as amended
(the "Securities Act"), with respect to the shares of Common Stock, $.025 par
value, of the Company (the "Common Stock") offered hereby. This Prospectus does
not contain all the information set forth in the Registration Statement, certain
parts of which have been omitted in accordance with the rules and regulations of
the Commission, and the exhibits relating thereto, which have been filed with
the Commission. Copies of the Registration Statement and the exhibits are on
file at the offices of the Commission and may be obtained upon payment of the
fees prescribed by the Commission, or examined without charge at the public
reference facilities of the Commission described above.
No person is authorized in connection with the offering made hereby to give
any information or to make any representation not contained or incorporated by
reference in this Prospectus, and any information or representation not
contained or incorporated herein must not be relied upon as having been
authorized by the Company, the Selling Stockholders set forth under "Selling
Stockholders" or any underwriter. This Prospectus does not constitute an offer
to sell or a solicitation of any offer to buy by any person in any jurisdiction
in which it is unlawful for such person to make such an offer or solicitation.
Neither the delivery of this Prospectus at any time nor any sale made hereunder
shall under any circumstance imply that the information herein is correct as of
any date subsequent to the date hereof.
- 4 -
<PAGE>
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by the Company with the Commission pursuant
to the Exchange Act are incorporated in this Prospectus by reference:
(a) The Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 1995;
(b) The Company's Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 1996.
(c) The Company's Proxy Statement dated as of May 13,
1996.
All documents filed by the Company pursuant to Section 13(a), 13(c), 14 or
15(d) of the Exchange Act subsequent to the date of this Prospectus and prior to
the termination of this offering shall be deemed to be incorporated by reference
in this Prospectus and to be a part hereof from the date of filing such
documents. Any statement contained in a document incorporated by reference
herein shall be deemed to be modified or superseded for purposes of this
Prospectus to the extent that a statement contained herein, or in any other
subsequently filed document that also is incorporated by reference herein,
modifies or supersedes such statement. Any such statement so modified or
superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Prospectus.
The Company will furnish, without charge, to any person to whom a copy of
this Prospectus is delivered, including any beneficial owner, upon such person's
written or oral request, a copy of any and all of the information filed by the
Company that has been incorporated by reference in this Prospectus (not
including exhibits to the information that is incorporated by reference herein
unless such exhibits are specifically incorporated by reference in such
information). Requests for such copies should be directed to the Company at 400
Rabro Drive East, Hauppauge, New York 11788, Attention Corporate Secretary
(telephone number (516) 582-5900).
- 5 -
<PAGE>
PROSPECTUS SUMMARY
The following summary is qualified in its entirety by the more detailed
information appearing elsewhere in this Prospectus.
The Company ................. Graham-Field Health Products, Inc. and its
wholly owned subsidiaries (collectively,
the "Company") manufacture, market and
distribute medical, surgical and a broad
range of other health care products for
hospital, physician and home use. The
Company markets and distributes approxi-
mately 22,000 products under its own
brand names and under suppliers' names.
The Company's products are marketed to
approximately 16,000 customers, principal-
ly hospital, physician and home health care
dealers, health care product wholesalers
and retailers, including drug stores, and
home shopping relating businesses.
Common Stock Offered ......... Up to 50,000 shares by the Selling Stock-
holders.
Offering Price ............... All or a part of the shares of Common
Stock offered hereby by the Selling Stock-
holders may be sold from time to time in
amounts and on terms to be designated by
the Selling Stockholders at the time of sale
or in the open market on the New York
Stock Exchange.
Common Stock Outstanding........ 14,220,808 shares of Common Stock.
Selling Stockholders............ Tyler E. Schueler
John D. Shepherd
New York Stock Exchange Symbol.. GFI.
Use of Proceeds................. The Company will not receive any of the
proceeds from the sale by the Selling
Stockholders of the shares of the Common
Stock offered hereby.
- 6 -
<PAGE>
THE COMPANY
The Company and its wholly owned subsidiaries (collectively, the "Company")
manufacture, market and distribute medical, surgical and a broad range of other
health care products for hospital, physician and home use. The Company markets
and distributes approximately 22,000 products under its own brand names and
under suppliers' names. The Company's products are marketed to approximately
16,000 customers, principally hospital, nursing home, physician and home health
care dealers, health care product wholesalers and retailers, including drug
stores, and home-shopping related businesses. During the five years ended
December 31, 1995, the number of products offered by the Company expanded from
approximately 14,000 to approximately 22,000. The expansion of the number of
products offered is primarily the result of an increase in the number of
distributorship agreements with suppliers and acquisitions of other companies
and product lines.
The Company's principal products and product lines include
sphygmomanometers (blood pressure measuring devices), stethoscopes, ECG
instruments, electronic thermometers, infrared heat treatment devices, durable
medical equipment (such as ambulatory aids, bathroom safety equipment and
wheelchairs), adult incontinence products, nutritional supplements, specialty
cushions and mattresses for the treatment and prevention of pressure sores,
medicated and rubber elastic bandages, respiratory equipment and supplies,
urologicals, ostomy products, infection control products, first aid supplies,
laboratory supplies, antiseptics and topical anesthetics and sterile disposable
medical products. By offering a wide range of products from a single source, the
Company enables its customers to reduce their costs associated with purchasing,
including transaction, freight and inventory expenses.
On May 31, 1991, the Company acquired 90% of the outstanding stock of
Horizon International Health Care, Inc., formerly known as AquaTherm Products
Corporation ("Aquatherm"), a manufacturer and distributor of deodorizers, and
pressure control products for the treatment or prevention of decubitus ulcers
(pressure sores). The Company acquired the remaining 10% of the outstanding
stock of AquaTherm on June 11, 1991. The total purchase price for the
outstanding stock of AquaTherm was $2,356,000. In connection with the
acquisition of AquaTherm, the Company entered into certain Stock Option
Agreements with each of Tyler E. Schueler and John D. Shepherd (collectively,
the "Selling Stockholders") dated as of May 31, 1991 (collectively, the "Stock
Option Agreements"), pursuant to which each of the Selling Stockholders was
granted a stock option to purchase 25,000 shares of the Common Stock at an
exercise price equal to the fair market value of the Common Stock on the date of
grant.
- 7 -
<PAGE>
The Company was organized under the laws of the State of Delaware on April
6, 1981 under the name, Patient Technology, Inc. On May 27, 1988, the Company
changed its name to Graham-Field Health Products, Inc. Except where the context
otherwise requires, the word "Company" as used herein includes all of its
subsidiaries. The Company's executive offices are located at 400 Rabro Drive
East, Hauppauge, New York 11788 and its telephone number is (516) 582-5900.
- 8 -
<PAGE>
USE OF PROCEEDS
The Company will not receive any of the proceeds from the sale by the
Selling Stockholders of the Shares of the Common Stock Offered hereby.
- 9 -
<PAGE>
SELLING STOCKHOLDERS
The Selling Stockholders acquired 50,000 shares of the Common Stock offered
hereby from the Company in connection with the exercise as of May 31, 1996, of
certain stock options granted to each of the Selling Stockholders pursuant to
the Stock Option Agreements. The Company has agreed to register the Common Stock
offered hereby, and may from time to time supplement or amend this Prospectus,
as required, to provide other information with respect to the Selling
Stockholders.
On May 31, 1991, the Company entered into certain consulting agreements
with each of the Selling Stockholders for a term of three (3) years. Under the
consulting agreements, each of the Selling Stockholders was paid an annual
consulting fee of $25,000 for services rendered to the Company. The consulting
agreements expired in accordance with their terms.
The table set forth below contains certain information regarding ownership
of the Company's Common Stock by the Selling Stockholders. The Selling
Stockholders may offer all or part of the Common Stock which they hold pursuant
to the offering contemplated by this Prospectus and because their offering is
not being underwritten on a firm commitment basis no estimate can be given as to
the amount of the Common Stock that will be held by Selling Stockholders upon
termination of this offering.
Percentage of
Shares Owned Shares Owned
Prior to Prior to Shares Being
Stockholder Offering Offering Offered
- ----------- ---------- ------------- -----------
Tyler E. Schueler 25,000 * 25,000
John D. Shepherd 25,000 * 25,000
------ ------
Total 50,000 * 50,000
====== ======
===============================================================================
* Less than one (1) percent.
- 10 -
<PAGE>
PLAN OF DISTRIBUTION
The Company will not receive any of the proceeds from the sale by the
Selling Stockholders of the Common Stock offered hereby. Any or all of the
shares of Common Stock may be sold from time to time (i) to or through
underwriters or dealers, (ii) directly to one or more other purchasers, (iii)
through agents on a best-efforts basis, or (iv) through a combination of any
such methods of sale. The Selling Stockholders and any such underwriters,
dealers or agents that participate in the distribution of the Common Stock may
be deemed to be underwriters within the meaning of the Securities Act, and any
profit on the sale of the Common Stock by them and any discounts, commissions or
concessions received by them may be deemed to be underwriting discounts and
commissions under the Securities Act. The Common Stock may be sold from time to
time in one or more transactions at a fixed offering price, which may be
changed, or at varying prices determined at the time of sale or at negotiated
prices. Such prices will be determined by the Selling Stockholders or by an
agreement between the Selling Stockholders and underwriters or dealers. Brokers
or dealers acting in connection with the sale of Common Stock contemplated by
this Prospectus may receive fees or commissions in connection therewith.
At the time a particular offer of Common Stock is made, to the extent
required, a supplement to this Prospectus will be distributed which will
identify and set forth the aggregate number of shares of Common Stock being
offered and the terms of the offering, including the name or names of any
underwriters, dealers or agents, the purchase price paid by any underwriter for
Common Stock purchased from the Selling Stockholders, any discounts, commissions
and other items constituting compensation from the Selling Stockholders and/or
the Company and any discounts, commissions or concessions allowed or reallowed
or paid to dealers, including the proposed selling price to the public. Such
supplement to this Prospectus and, if necessary, a post-effective amendment to
the Registration of which this Prospectus is a part, will be filed with the
Commission to reflect the disclosure of additional information with respect to
the distribution of the Common Stock.
The outstanding Common Stock is, and the Common Stock offered hereby will
be, listed on the NYSE.
Under applicable rules and regulations under the Exchange Act, any person
engaged in a distribution of the Common Stock may not simultaneously engage in
market making activities with respect to the Common Stock for a period of nine
business days prior to the commencement of such distribution. In addition and
with limiting the foregoing, the Selling Stockholders and any person
participating in the distribution of the Common Stock will be subject to
- 11 -
<PAGE>
applicable provisions of the Exchange Act and the rules and regulations
thereunder, including without limitation rules 10b-6 and 10b-7, which provisions
may limit the timing of purchases and sales of the Common Stock by the Selling
Stockholders or any such other person.
In order to comply with certain states' securities laws, if applicable, the
Common Stock will be sold in such jurisdictions only through registered or
licensed brokers or dealers. In certain states the Common Stock may not be sold
unless it has been registered or qualified for sale in such state, or unless an
exemption from registration or qualification is available.
Pursuant to an agreement with the Selling Stockholders, the Company has
agreed to file the Registration Statement of which the Prospectus is a part with
the Commission and use its best efforts to have it declared effective. Under the
terms of the agreement with the Selling Stockholders, the Company has agreed to
use its best efforts to keep such Registration Statement continuously effective
for a period of up to one year from the date the Registration Statement is first
declared effective by the Commission.
Pursuant to the agreement with the Selling Stockholders, the Selling
Stockholders have agreed to pay any and all expenses incident to the performance
of or compliance with such agreement including, among other things, registration
and filing fees, fees and expenses incurred in connection with compliance with
securities or blue sky laws of the applicable states, fees and disbursements of
counsel and independent public accountants for the Company, the fees and
disbursements of counsel to the Selling Stockholders, underwriting discounts and
commissions, and transfer taxes, if any.
- 12 -
<PAGE>
LEGAL MATTERS
The legality of the issuance of the Common Stock offered hereby will be
passed upon for the Company by The Law Firm of Robert E. Lesser.
- 13 -
<PAGE>
EXPERTS
The consolidated financial statements and schedule of Graham-Field Health
Products, Inc. (the "Company") appearing in the Company's Annual Report (Form
10-K) for the year ended December 31, 1995, have been audited by Ernst & Young
LLP, independent auditors, as set forth in their report thereon included therein
and incorporated herein by reference. Such consolidated financial statements and
schedule are incorporated herein by reference in reliance upon such report
given upon the authority of such firm as experts in accounting and auditing.
- 14 -
<PAGE>
MATERIAL CHANGES
On June 17, 1996, the Company entered into an agreement in principle with
Everest & Jennings International Ltd. ("Everest & Jennings") a manufacturer of
wheelchairs, and BIL (Far East Holdings) Limited ("BIL"), an investment company
and the majority stockholder of Everest & Jennings, to acquire Everest &
Jennings in a merger transaction. The terms of the proposed transaction provide
that the stockholders of Everest & Jennings will receive one share of common
stock of the Company in exchange for each four shares of the common stock of
Everest & Jennings, and $2.00 for each share of common stock of Everest &
Jennings. In connection with the acquisition of all of the issued and
outstanding shares of the common stock of Everest & Jennings, the Company will
issue a maximum of approximately 1.8 million shares and $14.4 million. The
merger consideration will be reduced if the value of the cash consideration and
shares of common stock of the Company to be issued in exchange for each share of
common stock of Everest & Jennings exceeds $5.00 as of the closing date.
BIL will receive additional shares of common stock of the Company in an
amount up to 1.9 million shares to be valued at the greater of $13.00 per share
or the average market price of the common stock of the Company for the ten (10)
consecutive trading days prior to the closing date, in exchange for the
repayment of all debt of Everest & Jennings in the approximate amount of $25
million to the Hong Kong and Shanghai Banking Corporation Limited. As part of
the transaction, all debt of Everest & Jennings to BIL and all Convertible
Preferred Stock of Everest & Jennings held by BIL will be exchanged for
approximately $60 million of Convertible Preferred Stock of the Company (the
"Convertible Preferred Stock"). The Convertible Preferred Stock will yield a
dividend at the rate of 2% per year, which will be paid at the option of the
Company either in cash or common stock. The Convertible Preferred Stock will be
convertible into common stock of the Company at a conversion price of $20.00 per
share during the five (5) year period following the closing and, if the
Convertible Preferred Stock has not converted during such period, the
Convertible Preferred Stock will automatically convert on the fifth anniversary
date of the closing at a conversion rate of $15.50. Immediately after the
transaction and after giving effect to the conversion of the Convertible
Preferred Stock, BIL will own approximately 30% of the common stock of the
Company. The transaction, which is currently anticipated to be completed in
November 1996, is subject to, among other things, due diligence, approval by the
Board of Directors of the Company and Everest & Jennings, the negotiation and
execution of definitive documentation, the approval by the stockholders of the
Company and Everest & Jennings, the receipt of certain corporate and regulatory
approvals, and the satisfaction of other customary terms and conditions. No
assurances can be provided that the transaction will be consummated.
- 15 -
<PAGE>
On June 25, 1996, the Company entered into an agreement in principle with
V.C. Medical Distributors Inc. ("V.C. Medical"), a wholesale distributor of
medical products in Puerto Rico, to acquire substantially all of the assets of
V.C. Medical for a purchase price of approximately $1.5 million, consisting of
cash in the amount of $1,250,000 with the balance payable in shares of common
stock of Graham-Field. As additional consideration, Graham-Field will pay
$500,000 to V.C. Medical provided the business achieves certain earnings levels
during the one year period following the closing of the proposed transaction.
The transaction, which is currently anticipated to be completed in August 1996,
is subject to, among other things, due diligence, approval by the Board of
Directors of Graham-Field, the negotiation and execution of definitive
documentation, the receipt of certain corporate and regulatory approvals, and
the satisfaction of other customary terms and conditions.
- 16 -
<PAGE>
LEGAL PROCEEDINGS
On May 21, 1996, the Company was sued by Minnesota Mining
& Manufacturing Company ("3M") in a claim purportedly arising under
federal, state and common law trademark, false advertising, and
unfair competition laws, as well as for brach of, and interference with,
contracts. 3M alleges that the Company is selling 3M products in
violation of federal and state law, and seeks monetary damages in an
unspecified amount, as well as injunctive relief against the Company's
continued sale of 3M products. The claim was filed in the Southern District
of New York. The Company vigorously denies the allegations of 3M's complaint,
and has filed an answer denying the allegations of wrongdoing and asserting
affirmative defenses. In addition, the Company has asserted counteclaims
against 3M under federal antitrust laws, as well as an unfair competition claim.
In June 1966, the Company was sued in a purported class action
captioned Kauffman v. Hogg in Delaware Chancery Court arising out of the
----------------
Company's announced proposed acquisition of Everest & Jennings. The Complaint
alleges that the Company aided and abetted breaches of fiduciary duty on the
part of Everest & Jennings' controlling stockholder and its directors in
connection with their negotiation of the proposed transaction. Plaintiff, a
stockholder at Everest & Jennings purports to seek to enjoin the transaction,
or alternatively, rescission, or an award of compensatory or rescissory damages.
The Company believes that it has valid defenses to the Complaint's allegations
of wrongdoing, and intends to vigorously defend the lawsuit.
- 17 -
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
An itemized statement of the estimated amount of all expenses in connection
with the distribution of the securities registered hereby is as follows:
Securities and Exchange Commission
registration fee....................................... $ 138
Legal fees and expenses.................................. 7,600
Accounting fees and expenses............................. 5,000
Transfer Agent's fees.................................... -0-
Miscellaneous............................................ 2,000
-------
Total.................................... $14,738
=======
- -------------------------
Item 15. Indemnification of Directors and Officers.
Under Section 145 of the Delaware General Corporation Law, a corporation
may indemnify any of its directors and officers against expenses (including
attorneys' fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by such person in connection with such action, suit or
proceeding (i) if such person acted in good faith and in a manner reasonably
believed to be in or not opposed to the best interests of the corporation and
(ii) in connection with any criminal action or proceeding if such person had no
reasonable cause to believe such conduct was unlawful. In actions brought by or
in the right of the corporation, however, Section 145 provides that no
indemnification may be made in respect of any claim, issue or matter as to which
such person shall have been adjudged to be liable to the corporation only to the
extent that, the Court of Chancery of the State of Delaware or the court in
which such action or suit was brought shall determine upon application that,
despite the adjudication of liability but in view of all the circumstances of
the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper.
Article V of the Company's By-laws requires that the Company indemnify its
directors and officers for certain liabilities incurred in the performance of
their duties on behalf of the Company to the fullest extent permitted or
required by the Delaware General Corporation Law.
The Company's Certificate of Incorporation, as amended, provides that
directors of the Company shall not be personally
II-1
<PAGE>
liable to the Company or to its stockholders for monetary damages for (i) any
breach of the director's duty of loyalty to the Company or its stockholders,
(ii) acts or omissions not in good faith or that involve intentional misconduct
or a knowing violation of law, (iii) any act or omission where the liability of
the director is expressly provided for by certain statutes listed therein or
(iv) any transaction for which the director derived an improper personal
benefit.
The Company has a directors and officers liability insurance policy in
effect which covers certain claims against any officer or director of the
Company by reason of certain breaches of duty, neglect, errors or omissions
committed by such person in his capacity as an officer or director.
II-2
<PAGE>
Item 16. Exhibits
(a) Exhibits:
3.1 The Company's Certificate of Incorporation, as
amended, is incorporated by reference to
Exhibit 3(1) to the Company's Registration
Statement on Form S-1, which was declared
effective with the Securities and Exchange
Commission on June 21, 1991 (File No. 33-
40442).
3.2 The Company's By-Laws, as amended, are
incorporated by reference as an exhibit to
the Company's Current Report on Form 8-K
dated as of July 14, 1995.
5.1 Opinion of The Law Firm of Robert E. Lesser.
24.1 Consent of Ernst & Young LLP, independent
auditors.
24.3 Consent of The Law Firm of Robert E. Lesser
(to be included in the opinion filed as Exhib-
it 5.1).
25 Power of Attorney (included in the signature
pages to this Registration Statement).
II-3
<PAGE>
Item 17. Undertakings.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the provisions set forth in Item 15 above, or otherwise,
the registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to Section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental
change in the information set forth in the registration
statement;
(iii) To include any material information with
respect to the plan of distribution not previously
II-4
<PAGE>
disclosed in the registration statement or any material
change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the
registration statement is on Form S-3, Form S-8, and the information required to
be included in a post-effective amendment by those paragraphs is contained in
periodic reports filed by the registrant pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.
(2) That, for the purpose of determining any
liability under the Securities Act of 1933, each such
post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered
therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a
post-effective amendment any of the securities being
registered which remain unsold at the termination of the
offering.
II-5
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, Graham-Field
Health Products, Inc. certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-3 and has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Hauppauge, New York on August 1, 1996.
GRAHAM-FIELD HEALTH PRODUCTS, INC.
By:/s/Irwin Selinger
--------------------------------
Irwin Selinger, Chairman of the
Board and Chief Executive Officer
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Irwin Selinger as his or her true and lawful
attorney-in-fact and agent, with full power of substitution, for him or her and
in his or her name, place and stead, in any and all capacities, to sign any and
all amendments and post-effective amendments to this Registration Statement, and
to file the same with all exhibits thereto, unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing
requisite and necessary to be done in and about the premises, as fully to all
intents and purposes as he or she might or could do in person, hereby ratifying
and confirming all that said attorney-in-fact and agent may lawfully do or cause
to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities indicated and on the dates indicated.
Signatures Title Date
---------- ----- ----
/s/Irwin Selinger
- ----------------------
Irwin Selinger Chairman of the Board and August 1, 1996
Chief Executive Officer
(Principal Executive Officer
and Director)
/s/Gary M. Jacobs
- ----------------------
Gary M. Jacobs Vice President/Finance and August 1, 1996
Chief Financial Officer
(Principal Financial Officer)
II-6
<PAGE>
/s/David P. Delaney
- ----------------------
David P. Delaney, Jr. Director August 1, 1996
/s/Harold Lazarus
- ----------------------
Dr. Harold Lazarus Director August 1, 1996
/s/Louis A. Lubrano
- ----------------------
Louis A. Lubrano Director August 1, 1996
/s/Andrew A. Giordano
- ----------------------
Andrew A. Giordano Director August 1, 1996
/s/Robert Spiegel
- ----------------------
Robert Spiegel Director August 1, 1996
/s/Marcel Newfield
- ----------------------
Marcel Newfield Director August 1, 1996
/s/Steven D. Levkoff
- ----------------------
Steven D. Levkoff Director August 1, 1996
/s/Donald Press
- ----------------------
Donald Press Director August 1, 1996
II-7
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
EXHIBITS
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GRAHAM-FIELD HEALTH PRODUCTS, INC.
<PAGE>
INDEX TO EXHIBITS
Exhibit No. Description
3.1 The Company's Certificate of Incorporation, as amended, is
incorporated by reference to Exhibit 3(1) to the Company's
Registration Statement on Form S-1, which was declared
effective with the Securities and Exchange Commission on
June 21, 1991 (File No. 33-40442).
3.2 The Company's By-Laws, as amended, are incorporated by
reference as an exhibit to the Company's Current Report on
Form 8-K dated as of July 14, 1995.
5.1 Opinion of The Law Firm of Robert E. Lesser, as to the
validity of securities being registered.
24.1 Consent of Ernst & Young LLP, independent auditors.
24.3 Consent of The Law Firm of Robert E. Lesser
(included as Exhibit 5).
25 Power of Attorney (included in the signature pages to this
Registration Statement).
EXHIBIT 5.1
The Law Firm of
Robert E. Lesser
488 Madison Avenue
New York, New York 10022
July 31, 1996
Graham-Field Health Products, Inc.
400 Rabro Drive East
Hauppauge, New York 11788
Gentlemen:
You have requested our opinion, as counsel for Graham- Field Health
Products, Inc., a Delaware corporation (the "Company"), in connection with the
preparation and filing of a Registration Statement of the Company on Form S-3
(the "Registration Statement") for the registration of 50,000 shares (the
"Shares") of the common stock, par value $.025 per share, of the Company under
the Securities Act of 1933, as amended (the "Act"). The Registration Statement
relates to the offering of the Shares by certain selling stockholders (the
"Selling Stockholders") as described in the Registration Statement.
We have examined such records and documents and made such examination of
law as we have deemed relevant in connection with this opinion. Bases upon such
examination, it is our opinion that:
1. The Company is a corporation duly incorporated and
validly existing under the laws of the State of
Delaware.
2. The Shares proposed to be sold by the Selling
Stockholders as described in the Registration
Statement have been duly authorized and validly
issued, and when sold as described in the
Registration Statement, will be fully paid and non-
assessable.
<PAGE>
Graham-Field Health Products, Inc.
July 31, 1996
Page 2
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the reference to our firm under the caption "Legal
Matters" in the Registration Statement. In so doing, we do not admit that we are
in the category of persons whose consent is required under Section 7 of the Act
or the rules and regulations of the Securities and Exchange Commission
promulgated thereunder.
Very truly yours,
The Law Firm of Robert E. Lesser
/s/Robert E. Lesser
----------------------------------
EXHIBIT 24.1
Consent of Independent Auditors
We consent to the reference to our firm under the caption "Experts" in the
Registration Statement (Form S-3) and related Prospectus of Graham-Field Health
Products, Inc. for the registration of 50,000 shares of its common stock and to
the incorporation by reference therein of our report dated March 8, 1996, with
respect to the consolidated financial statements and schedule of Graham-Field
Health Products, Inc. included in its Annual Report (Form 10-K) for the year
ended December 31, 1995, filed with the Securities and Exchange Commission.
ERNST & YOUNG LLP
Melville, New York
July 31, 1996
